Framework for Stable Pharmaceutical Supply During the COVID-19 Pandemic
First written in FY2020. 5 of 11 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2026: 1 of 12 companies on the "Worse" side.
2 other companies' latest entry also says "Other".
- FY2025Decline in Revenue from Contracted Vaccine DeliveryAnnual report
「Although there was a reversal of the gain from the reversal of the allowance for doubtful accounts for a major customer recorded in the previous year, the loss of revenue from contracted COVID-19 vaccine delivery services for the national and local governments, and the recognition of business investment expenses」
It identifies the loss of revenue from contracted COVID-19 vaccine delivery services compared with the previous year as a factor contributing to profit in the pharmaceutical wholesale business. - FY2025-H1Decline in Revenue from Contracted Vaccine DeliveryAnnual report
「Although there were negative impacts, including a decline in sales of COVID-19 treatments and test kits recorded in the same period of the previous year and revenue from contracted COVID-19 vaccine delivery services」
It states that sales of COVID-19 treatments and test kits recorded in the same period of the previous year, as well as revenue from contracted COVID-19 vaccine delivery services, declined. - FY2023-Q2Contracted Revenue Exceeded ForecastAnnual report
「In addition, revenue from contracted COVID-19 vaccine delivery services for the national and local governments, which continued from the previous fiscal year, also exceeded expectations.」
It states that contracted COVID-19 vaccine delivery services for the national and local governments continued and that the resulting revenue exceeded expectations. - FY2022AdvancedAnnual report
「In this environment, we focused on contracted COVID-19 vaccine delivery, basic vaccination-site operations and repackaging operations for the national and local governments, thereby fulfilling our social mission of helping bring the COVID-19 pandemic to an end.」
In addition to the stable supply system, it handled contracted vaccine delivery, vaccination-site operations and repackaging operations for the national and local governments. - FY2022-Q3RestatedAnnual report
「In this environment, we also focused on contracted COVID-19 vaccine delivery, basic vaccination-site operations and repackaging operations for the national and local governments, thereby fulfilling our social mission of helping bring the COVID-19 pandemic to an end.」
It continued to handle contracted COVID-19 vaccine delivery, vaccination-site operations and repackaging operations for the national and local governments. - FY2022-Q2Expansion into Vaccine-Related OperationsAnnual report
「In this environment, we also focused on contracted COVID-19 vaccine delivery, basic vaccination-site operations and repackaging operations for the national and local governments, thereby fulfilling our social mission of helping bring the COVID-19 pandemic to an end.」
It describes, in addition to the stable pharmaceutical supply system, the response to contracted COVID-19 vaccine delivery, vaccination-site operations and repackaging operations for the national and local governments. - FY2022-Q1RestatedAnnual report
「During the consolidated cumulative period under review, in order to maintain a stable supply system, we have made every effort, in line with the purpose of the Distribution Improvement Guidelines, to promote negotiations over per-item pricing and conduct transactions at appropriate prices that reflect the value of pharmaceuticals.」
It continued its policy of maintaining a stable pharmaceutical supply system in conjunction with negotiations on unit prices for individual products and transactions at appropriate prices. - FY2021-Q3RestatedAnnual report
「During the spread of COVID-19, our Group placed the social mission of ensuring a stable supply of pharmaceuticals above all else, suspended sales activities and supplied pharmaceuticals through a logistics-focused operating structure based on rotating shifts.」
It continued to respond by suspending sales activities during the spread of COVID-19 and supplying pharmaceuticals through a logistics-focused operating structure based on rotating shifts. - FY2021-Q2RestatedAnnual report
「During the spread of COVID-19, our Group placed the social mission of ensuring a stable supply of pharmaceuticals above all else, suspended sales activities and supplied pharmaceuticals through a logistics-focused operating structure based on rotating shifts.」
It continued to respond by suspending sales activities during the spread of COVID-19 and supplying pharmaceuticals through a logistics-focused operating structure based on rotating shifts. - FY2021-Q1RestatedAnnual report
「During the spread of COVID-19, our Group placed the social mission of ensuring a stable supply of pharmaceuticals above all else, suspended sales activities and supplied pharmaceuticals through a logistics-focused operating structure based on rotating shifts.」
It continued to respond by suspending sales activities during the spread of COVID-19 and supplying pharmaceuticals through a logistics-focused operating structure based on rotating shifts. - FY2020First statedAnnual report
「In March 2020, we established COVID-19 task forces at our principal operating companies, Vital Net, Inc. and KSK Co., Ltd. To ensure a stable supply of pharmaceuticals, we increased product inventories above normal levels and, during the state of emergency, established a logistics-focused operating structure based on rotating shifts and other measures.」
As a response to the spread of COVID-19, it established task forces, increased inventories and implemented a rotating-shift logistics system.